Skip to content

Patient Reported Outcomes for Vascular Malformations EmbolizatioN (PROVEN)

Patient Reported Outcomes for Vascular Malformations EmbolizatioN (PROVEN)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04104464
Enrollment
200
Registered
2019-09-26
Start date
2019-07-22
Completion date
2028-07-31
Last updated
2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular Malformations, VM - Vascular Malformation

Keywords

vascular malformation, VM

Brief summary

The purpose of this study is to develop a standardized assessment for patients treated for venous malformations (VM). Venous malformations result from the abnormal development of veins which may result in pain, swelling, bleeding, functional impairment, disfigurement, and psychological distress. The impact of VM on patient quality of life varies based on the location and size of the malformation. A patient reported outcome (PRO) is a patient's own account of patient's health condition. PRO measures are valued to clinicians, as many treatment effects are known only to the patient. No studies to date have analyzed the validity of existing PRO measures for VM patients. Current assessment does not include all symptoms or take in to account the relevance of VM location. Past studies show a discrepancy between treatment outcomes reported by patients and physicians. Therefore, there is a need to develop VM-specific PROs to better understand the effectiveness and benefits of treatment for VM.

Interventions

None listed

Sponsors

Johns Hopkins University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Male and Female pediatric patients, aged between 0-17 with diagnosis of vascular malformations. * Male and Female adult patients aged 18-100 with diagnosis of vascular malformations. * Vascular malformation symptoms significant enough to seek treatment.

Exclusion criteria

* Patients with extensive VM not suitable for sclerotherapy. * Prior therapy for treatment of a VM within 3 months. * Condition or impairment that may render the patient unable to take part in the study (e.g. cognitive, sight, hearing, etc.).

Design outcomes

Primary

MeasureTime frameDescription
Change in patient reported VM pain1 month, 3 months and 6 months post-procedure; and all subsequent visits up to 1 yearPatients are asked to rate pain associated with VM during the past seven days on a 0-10 scale.
Change in patient reported VM impact on daily life1 month, 3 months and 6 months post-procedure; and all subsequent visits up to 1 yearPatients are asked to rate the impact that their VM has on daily life with the options "Not at all", "A little bit", "Somewhat", "Quite a bit" or "Very Much".
Change in patient reported efficacy of treatment1 month, 3 months and 6 months post-procedure; and all subsequent visits up to 1 yearPatients are asked to rate the efficacy of their treatment with the options "Not at all", "A little bit", "Somewhat", "Quite a bit" or "Very Much".
Change in patient reported relevancy of the PROVEN Questionnaire1 month, 3 months and 6 months post-procedure; and all subsequent visits up to 1 yearPatients are asked to rate the personal relevancy and clarity of the survey questions with the options "Not at all", "A little bit", "Somewhat", "Quite a bit" or "Very Much".

Countries

United States

Contacts

CONTACTClifford R Weiss, MD
cweiss@jhmi.edu410-614-0601
CONTACTHannatu A Bwayili, BS
hbwayil1@jh.edu
PRINCIPAL_INVESTIGATORClifford R Weiss, MD

Johns Hopkins University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 15, 2026